Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 108

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Neuromuscular blockade

Not recruiting

Study on the Effectiveness of Dexmedetomidine, Ropivacaine, and Dexamethasone for Pain Relief in Patients Undergoing Shoulder Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Algemeen ziekenhuis Rivierenland

Muscular dystrophy

Not recruiting

Gene Therapy Study for Patients with Limb-Girdle Muscular Dystrophy Using GNT0006

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Atamyo Therapeutics

Spinal muscular atrophy

Not recruiting

Study of Risdiplam for Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Severe myoclonic epilepsy of infancy+1

Not recruiting

Study on Soticlestat for Children and Adults with Dravet or Lennox-Gastaut Syndrome Previously Treated with Fenfluramine

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.

Narcolepsy

Not recruiting

Study on Blood Pressure Changes in Narcolepsy Patients Switching from High-Sodium Oxybate to JZP258 (Oxybate Mixed-Salt Formulation)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Oxybate
  • Sponsor:Jazz Pharmaceuticals PLC

Dementia of the Alzheimer's type uncomplicated

Not recruiting

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.

Dementia Alzheimer's type

Not recruiting

Study on the Effects of Semaglutide on Inflammation in Patients with Alzheimer's Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Migraine

Not recruiting

Study on Galcanezumab for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Galcanezumab
  • Sponsor:Eli Lilly & Co.

Migraine

Not recruiting

Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Galcanezumab
  • Sponsor:Eli Lilly & Co.

Multiple sclerosis

Not recruiting

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Natalizumab
  • Sponsor:Helse Bergen HF

Metastases to central nervous system+2

Not recruiting

Study on JDQ443 for Patients with KRAS G12C+ Non-Small Cell Lung Cancer and Brain Metastases

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Academisch Ziekenhuis Maastricht

Tuberous sclerosis complex+2

Not recruiting

Study on Cannabidiol Oral Solution for Infants with Tuberous Sclerosis, Dravet Syndrome, or Lennox-Gastaut Syndrome Experiencing Uncontrolled Seizures

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Jazz Pharmaceuticals Research UK Limited

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.